InsiderTrades.com logo
Bear or bull market, this highly successful trader has shocking new forecast 
From Legacy Research   |   Ad
Nobody believed Larry Benedict’s prediction in February 2020.

The DOW plunged 3.5%, and he told CNBC, “It seems like there’s much more to come.” Within a month, the market plummeted 34%. Then, nobody believed Larry at the start of this year, either. He predicted that “all the indexes will be negative for the year,” with the Nasdaq leading the way. Once again, he was spot-on.
Click here to watch his interview right now.

NVCT Insider Trading

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): $995,524.43
Insider Selling (Last 12 Months): $0.00

Nuvectis Pharma Insider Trading History Chart

This chart shows the insider buying and selling history at Nuvectis Pharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Nuvectis Pharma Share Price & Price History

Current Price: $7.51
Price Change: ▼ Price Decrease of -0.08 (-1.05%)
As of 12/9/2022 01:00 AM ET

This chart shows the closing price history over time for NVCT up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Our Top 5 Microcap Stocks
From Weekly Investor Alerts   |   Ad
Microcap stocks tend to be an under-researched area… Which increases the odds of discovering attractive investment opportunities.

Just like these 5 which appear to be in an excellent position to see a surge in share price.
>>> See All 5 Here
pixel

Nuvectis Pharma Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/30/2022Ron BentsurCEOBuy150$7.45$1,117.503,015,459View SEC Filing Icon  
11/28/2022Ron BentsurCEOBuy150$7.40$1,110.003,015,159View SEC Filing Icon  
11/25/2022Ron BentsurCEOBuy150$7.38$1,107.003,015,009View SEC Filing Icon  
11/17/2022Ron BentsurCEOBuy250$7.24$1,810.003,014,359View SEC Filing Icon  
11/16/2022Shay ShemeshInsiderBuy150$7.10$1,065.001,245,215View SEC Filing Icon  
11/10/2022Ron BentsurCEOBuy1,000$7.07$7,070.003,014,109View SEC Filing Icon  
9/30/2022Ron BentsurCEOBuy500$7.46$3,730.003,013,109View SEC Filing Icon  
9/28/2022Ron BentsurCEOBuy500$7.23$3,615.003,012,609View SEC Filing Icon  
9/26/2022Ron BentsurCEOBuy500$7.69$3,845.003,012,109View SEC Filing Icon  
9/23/2022Ron BentsurCEOBuy1,000$7.93$7,930.003,011,609View SEC Filing Icon  
9/23/2022Shay ShemeshInsiderBuy220$7.87$1,731.401,245,065View SEC Filing Icon  
8/29/2022Ron BentsurCEOBuy1,000$9.07$9,070.003,008,909View SEC Filing Icon  
8/23/2022Ron BentsurCEOBuy500$9.00$4,500.003,007,909View SEC Filing Icon  
8/18/2022Ron BentsurCEOBuy14,426$8.58$123,775.083,002,409View SEC Filing Icon  
8/11/2022Ron BentsurCEOBuy19,669$8.40$165,219.602,987,983View SEC Filing Icon  
6/28/2022Ron BentsurCEOBuy300$11.82$3,546.002,964,614View SEC Filing Icon  
6/24/2022Ron BentsurCEOBuy400$12.18$4,872.002,964,314View SEC Filing Icon  
6/22/2022Ron BentsurCEOBuy100$13.10$1,310.002,963,714View SEC Filing Icon  
5/26/2022Ron BentsurCEOBuy500$15.90$7,950.002,963,114View SEC Filing Icon  
5/20/2022Ron BentsurCEOBuy1,000$16.28$16,280.002,962,614View SEC Filing Icon  
5/20/2022Shay ShemeshInsiderBuy300$16.54$4,962.001,241,435View SEC Filing Icon  
5/18/2022Ron BentsurCEOBuy1,700$19.36$32,912.002,961,414View SEC Filing Icon  
5/16/2022Ron BentsurCEOBuy1,000$19.32$19,320.002,959,404View SEC Filing Icon  
5/16/2022Shay ShemeshInsiderBuy100$19.28$1,928.001,240,993View SEC Filing Icon  
5/12/2022Kenneth HobermanDirectorBuy6,000$17.40$104,400.0055,140View SEC Filing Icon  
5/12/2022Kenneth HobermanDirectorBuy6,000$17.40$104,400.0055,140View SEC Filing Icon  
5/12/2022Ron BentsurCEOBuy12,245$16.99$208,042.552,957,704View SEC Filing Icon  
5/12/2022Shay ShemeshInsiderBuy1,278$15.85$20,256.301,240,893View SEC Filing Icon  
3/28/2022Ron BentsurCEOBuy4,000$7.05$28,200.00View SEC Filing Icon  
3/17/2022Ron BentsurCEOBuy7,000$7.63$53,410.00View SEC Filing Icon  
2/14/2022Ron BentsurCEOBuy8,000$5.88$47,040.00View SEC Filing Icon  
See Full Table
4 Down Market Stocks
From ProTrading Research   |   Ad
There are 4 stocks positioned well to help you weather the storm – and continue to grow your wealth – during a down market.

Enter your email and we’ll send you the names & ticker symbols of all four stocks straight to your email inbox…

Click here for all 4 stocks.
>>>
pixel

SEC Filings (Institutional Ownership Changes) for Nuvectis Pharma (NASDAQ:NVCT)

13.97% of Nuvectis Pharma stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at NVCT by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Nuvectis Pharma Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/15/2022Vanguard Group Inc.27,061$0.19M0.0%+16.4%0.185%Search for SEC Filing on Google Icon
11/15/2022BlackRock Inc.14,003$100K0.0%+94.5%0.096%Search for SEC Filing on Google Icon
11/10/2022Tower Research Capital LLC TRC 4,052$29K0.0%+216.8%0.028%Search for SEC Filing on Google Icon
11/4/2022Ronit Capital LLP562,547$3.99M5.4%+34.2%3.843%Search for SEC Filing on Google Icon
10/14/2022Baldwin Brothers LLC MA133,000$0.94M0.1%+9.9%0.908%Search for SEC Filing on Google Icon
8/15/2022State Street Corp11,700$0.13M0.0%N/A0.092%Search for SEC Filing on Google Icon
8/15/2022Citadel Advisors LLC35,069$0.39M0.0%N/A0.276%Search for SEC Filing on Google Icon
8/4/2022Ronit Capital LLP419,282$4.70M6.7%-23.8%3.297%Search for SEC Filing on Google Icon
7/18/2022Baldwin Brothers LLC MA121,000$1.36M0.2%N/A0.951%Search for SEC Filing on Google Icon
5/17/2022Virtu Financial LLC11,365$84K0.0%N/A0.089%Search for SEC Filing on Google Icon
5/12/2022BlackRock Inc.7,872$59K0.0%N/A0.062%Search for SEC Filing on Google Icon
5/11/2022Ronit Capital LLP550,000$4.08M5.1%N/A4.325%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Nuvectis Pharma logo
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
Read More on Nuvectis Pharma

Today's Range

Now: $7.51
Low: $7.51
High: $7.51

50 Day Range

MA: $7.08
Low: $6.21
High: $7.64

52 Week Range

Now: $7.51
Low: $3.08
High: $20.92

Volume

848 shs

Average Volume

450,513 shs

Market Capitalization

$109.96 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Nuvectis Pharma?

Nuvectis Pharma's top insider investors include:
  1. Ron Bentsur (CEO)
  2. Shay Shemesh (Insider)
  3. Kenneth Hoberman (Director)
Learn More about top insider investors at Nuvectis Pharma.

Who are the major institutional investors of Nuvectis Pharma?

Nuvectis Pharma's top institutional shareholders include:
  1. Ronit Capital LLP — 3.84%
  2. Baldwin Brothers LLC MA — 0.91%
  3. Vanguard Group Inc. — 0.18%
  4. BlackRock Inc. — 0.10%
  5. Tower Research Capital LLC TRC — 0.03%
Learn More about top institutional investors of Nuvectis Pharma stock.

Which major investors are buying Nuvectis Pharma stock?

In the previous quarter, NVCT stock was acquired by institutional investors including:
  1. Ronit Capital LLP
  2. Baldwin Brothers LLC MA
  3. BlackRock Inc.
  4. Vanguard Group Inc.
  5. Tower Research Capital LLC TRC
In the previous year, these company insiders have bought Nuvectis Pharma stock:
  1. Ron Bentsur (CEO)
  2. Shay Shemesh (Insider)
  3. Kenneth Hoberman (Director)
Learn More investors buying Nuvectis Pharma stock.
Q4 Earnings Announcements…
From Weekly Investor Alerts   |   Ad
That’s right… Q4 earnings announcements are coming… And these five microcap stocks appear to be in an excellent position to see a surge in share price.
>>> Click here to see all 5 stocks
pixel